[1]CurrentPatentAssignee:JIANGSUMINGTAIINVESTMENTGROUPLTD-CN102796079,2016,BLocationinpatent:Paragraph0021-0024
[2]CurrentPatentAssignee:HANSOHPHARMACEUTICALGROUPCOLTD-CN115197168,2022,ALocationinpatent:Paragraph0102-0104
[1]CurrentPatentAssignee:HANSOHPHARMACEUTICALGROUPCOLTD-CN111072636,2020,A
[1]CurrentPatentAssignee:HANSOHPHARMACEUTICALGROUPCOLTD-CN111072636,2020,A
[1]CurrentPatentAssignee:HANSOHPHARMACEUTICALGROUPCOLTD-CN111072636,2020,ALocationinpatent:Paragraph0042;0073-0084
Title: Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Journal: Cancer science 20140101
Title: Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501
Title: HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Journal: Leukemia 20101001
Title: Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100801
Title: [Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Abl wild type and IM-resistant cell lines in vitro].
Journal: Zhongguo shi yan xue ye xue za zhi 20081001
Title: Luo H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010 Oct;24(10):1807-9.
Title: Zhao J, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013 Nov 10.
Title: Gong A, et al. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010 Aug;38(8):1328-40.
